OR4F17

Across TCGA pan-cancer cohorts, OR4F17 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR4F17 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher OR4F17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4F17 expression acts as an unfavorable survival marker.

SCLC are the cancer types where OR4F17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.192	0.793	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

OR4F17–SCLC (DFS)

Open the SCLC breakdown →